Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918793 | 0.93 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4920157 | 0.89 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4919482 | 0.87 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4922113 | 0.85 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4921396 | 0.82 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4918672 | 0.77 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4914553 | 0.77 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4914753 | 0.77 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4921373 | 0.76 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4919220 | 0.76 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288659-B2 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2007-10-30 | — | — | US | disclosed |
| EP-1417189-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-12-14 | — | — | EP | disclosed |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI (FR) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, CBR1 | PSEN1 3790/4885PSEN2 4586/4885APH1B 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.